D-1862-2019 Class II Terminated

Recalled by Torrent Pharma Inc. — Basking Ridge, NJ

FDA drug recall D-1862-2019 was initiated by Torrent Pharma Inc. on Sep 6, 2019 and is designated Class II. Reason for recall: Failed Impurities/Degradation Specifications: High Out Of Specification results for impurities detected during routine stability testing. The recall status is terminated (terminated Nov 3, 2020). Affected quantity: 2472 bottles.

Recall details

Product Type
Drugs
Report Date
Sep 25, 2019
Initiation Date
Sep 6, 2019
Termination Date
Nov 3, 2020
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
2472 bottles

Product description

Anagrelide Capsules, USP, 0.5 mg, 100-count bottle, Rx only, Manufactured in India for: Torrent Pharma Inc., Basking Ridge, NJ 07920, NDC 13668-453-01.

Reason for recall

Failed Impurities/Degradation Specifications: High Out Of Specification results for impurities detected during routine stability testing.

Distribution pattern

Nationwide in the USA and Puerto Rico

Code information

Lot #: BFE2E003, Exp 08/31/2020

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1862-2019
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1862-2019. Report a data issue: hello@regdatalab.com.